Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.

Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.

Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.

Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.

Abstract: The invention features derivatives of R(?)-2-methoxy-11-hydroxyaporphines and methods of treating Parkinson's disease and sexual dysfunction therewith.

Abstract: The invention features derivatives of R(?)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.

Abstract: The invention features derivatives of R(?)-2-methoxy-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.

Abstract: The invention features derivatives of R(?)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.

Abstract: The invention features derivatives of R(—)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.

Abstract: The invention is based in part on the discovery that nonselective ? agonists that possess ? receptor-mediated effects in addition to their ? agonist effects can decrease cocaine self-administration more effectively and with fewer undesirable side effects than can highly selective ? agonists. The invention includes a number of new compounds having both nonselective ? opioid receptor agonist activity and additional activity at ? opioid receptors. These compounds are useful for the treatment of cocaine abuse, and can also be radiolabeled for use as imaging agents, e.g., the N-fluoroalkyl and iodoalkyl derivatives can be used, respectively, for positron emission tomography (PET) and single photon computed tomography (SPECT) brain imaging.

Abstract: This invention features opioid compounds having activity at kappa and mu receptors, methods for preparing the mu/kappa opioids, and methods for the treatment of pain or a dopamine dysregulation disease, such as schizophrenia, attention deficit hyperactivity disorder (ADHD), attention deficit hyperactivity disorder (ADD), Parkinson's disease, hyperprolactinemia, depression, and addiction.

Abstract: The invention is based in part on the discovery that nonselective ? agonists that possess ? receptor-mediated effects in addition to their ? agonist effects can decrease cocaine self-administration more effectively and with fewer undesirable side effects than can highly selective ? agonists. The invention includes a number of new compounds having both nonselective ? opioid receptor agonist activity and additional activity at ? opioid receptors. These compounds are useful for the treatment of cocaine abuse, and can also be radiolabeled for use as imaging agents, e.g., the N-fluoroalkyl and iodoalkyl derivatives can be used, respectively, for positron emission tomography (PET) and single photon computed tomography (SPECT) brain imaging.

Abstract: This invention features opioid compounds having activity at kappa and mu receptors, methods for preparing the mu/kappa opioids, and methods for the treatment of pain or a dopamine dysregulation disease, such as schizophrenia, attention deficit hyperactivity disorder (ADHD), attention deficit hyperactivity disorder (ADD), Parkinson's disease, hyperprolactinemia, depression, and addiction.

Abstract: The invention is based in part on the discovery that nonselective &kgr; agonists that possess &mgr; receptor-mediated effects in addition to their &kgr; agonist effects can decrease cocaine self-administration more effectively and with fewer undesirable side effects than can highly selective &kgr; agonists. The invention includes a number of new compounds having both nonselective &kgr; opioid receptor agonist activity and additional activity at &mgr; opioid receptors. These compounds are useful for the treatment of cocaine abuse, and can also be radiolabeled for use as imaging agents, e.g., the N-fluoroalkyl and iodoalkyl derivatives can be used, respectively, for positron emission tomography (PET) and single photon computed tomography (SPECT) brain imaging.

Abstract: Iodinated neuroprobes for mapping monoamine reuptake sites in the brain, and particularly iodinated neuroprobes that can also serve as radiotracers for use in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging of such reuptake sites, are disclosed. Precursors of radiolabeled iodinated neuroprobes, both with and without a radiotracer atom, and kits for preparing the radiolabeled iodinated neuroprobes are also disclosed.

Abstract: An iodinated neuroprobe is provided for mapping monoamine reuptake sites. The iodinated neuroprobe is of the formula: ##STR1## wherein R= ##STR2## wherein n=2-8; R'=C.sub.w H.sub.2w+1 wherein w=0-6 and C includes an isotope of carbon; andX=an isotope of Cl, an isotope of Br, an isotope of F, an isotope of I, or Sn(R".sub.1 R".sub.2 R".sub.3), whereinR".sub.1 =a C.sub.p H.sub.2p+1 group where p=1-6, or an aryl group;R".sub.2 =a C.sub.p H.sub.2p+1 group where p=1-6, or an aryl group; andR".sub.3 =a C.sub.p H.sub.2p+1 group where p=1-6, or an aryl group.Additionally, a precursor of a radiolabeled neuroprobe and a kit for preparing the iodinated neuroprobe are provided.

Abstract: Neuroprobes that include rhenium, manganese, and technetium for use in mapping monoamine reuptake sites are disclosed. Non-radioactive tricarbonylrheniumcyclopentadienyl (TRCp) or non-radioactive tricarbonylmanganesecyclopentadienyl (TMCp) phenyltropane analogs are synthesized for use as testing surrogates for radioactive technetium congeners. Ferrocenyl analogs of phenyltropane are disclosed as useful precursors for the preparation of novel tricarbonyltechnetiumcyclopentadienyl (TTCp) phenyltropane analogs in radioactive form.

Abstract: An iodinated neuroprobe is provided for mapping monoamine reuptake sites. The iodinated neuroprobe is of the formula: ##STR1## wherein: R=aryl, substituted aryl, heterocyclic, CO(CH.sub.2).sub.n Y, (CH.sub.2).sub.n CHF.sub.2, and (CF.sub.2).sub.n Y, wherein:Y=Cl, Br, I, (CH.sub.2).sub.m, aryl, substituted aryl, heterocyclic CO.sub.2 H, CO.sub.2 R.sup.3, CO.sub.2 NR.sup.3 R.sup.4, OH, OR.sup.3, CH(OR.sup.3).sub.2, CR.sup.3 (OR.sup.4).sub.2, OC0R.sup.3, OSO.sub.2 R.sup.3, OCONR.sup.3 R.sup.4, OCOOR.sup.3, CONR.sup.3 R.sup.4, NR.sup.3 R.sup.4, NR.sup.3 COR.sup.4, NR.sup.3 CO.sub.2 R.sup.4, NR.sup.3 CONR.sup.4 R.sup.5, NCS, NCO;R.sup.3, R.sup.4 and R.sup.5 =alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, or heterocyclic;m=3-8; andn=1-6;R'=C.sub.w H.sub.2w+1 wherein w=0-6 and C includes an isotope of carbon; andX=an isotope of Cl, an isotope of Br, an isotope of F, an isotope of I, or Sn(R".sub.1 R".sub.2 R".sub.3), whereinR".sub.1 =a C.sub.p H.sub.

Abstract: The present invention provides sulfur-containing xanthine derivatives which are 1,3-disubstituted with a C.sub.1 -C.sub.12 alkyl, which may be further substituted with a hydroxy, amino, or halo group, and are 8-substituted with either a cycloalkyl, furyl, thienyl, or substituted phenyl group. These derivatives possess increased selectivity or potency at adenosine receptors.

Abstract: An iodinated neuroprobe is provided for mapping monoamine reuptake sites. The iodinated neuroprobe is of the formula: ##STR1## wherein R=a C.sub.n H.sub.2n+1 group where n=0-6, an alkenyl group, a monofluoroalkyl group including .sup.n F where n=18 or 19, or a .sup.m C.sub.n H.sub.2n+1 group where n=1-6 and where m=11 or 14 for at least one .sup.m C;R'=a C.sub.n H.sub.2n+1 group where n=0-6, a p-iodophenylmethyl group, a p-iodophenylethyl group, a phenylmethyl group, or a phenylethyl group;X=an isotope of F, an isotope of Cl, an isotope of Br, an isotope of I, CH.sub.3, or Sn(R".sub.1 R".sub.2 R".sub.3);R".sub.1 =a C.sub.n H.sub.2n+1 group where n=1-6, or an aryl group;R".sub.2 =a C.sub.n H.sub.2n+1 group where n=1-6, or an aryl group;R".sub.3 =a C.sub.n H.sub.2n+1 group where n=1-6, or an aryl group; andY=H only if X is an isotope of I, or R' is a p-iodophenylmethyl group, or R' is a p-iodophenylethyl group, else Y=an isotope of I.Related analogs are also provided.